Solid lipospheres of doxorubicin and idarubicin

Cavalli, Roberta; Caputo, O.; Gasco, Maria Rosa

doi:10.1016/0378-5173(93)90313-5

Cited by 123 publications

(58 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these studies also showed that SLNs delivered reduced amount of drugs into Serpe, 2006;Ying, 2008;Wong, 2004Wong, , 2006aWong, , 2006bCavalli, 1993 Han, 2008ibuprofen Casadei, 2006Paolicelli, 2008idarubicin Cavalli, 1993insulin Battaglia, 2007Bi, 2009;Gallarate, 2008;Liu 2008,a,d,;Sarmento, 2007magnetite Hsu, 2008methotrexate Paliwal, 2008Ruckmani, 2006mitoxanthrone Lu, 2006nimesulide Bondi, 2009nitrendipine Bhaskar, 2009bKumar, 2007;Manjunath, 2006olanzapine Vivek, 2007oridonin Zhang, 2005oxymatrine Sun, 2007paclitaxel Dong, 2008Lee, 2007;Cavali, 2000;Stevens, 2004;Serpe, 2004;Chen, 2001 (2010) heart, lung, spleen, liver and kidney (Zara et al, 2000;Fundaro et al, 2000;, which suggest that biodistribution of drugs in SLNs can vary depending on the composition of SLNs.…”

Section: Biodistributionmentioning

confidence: 99%

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

Li¹,

Lim²,

Choi³

et al. 2010

Journal of Pharmaceutical Investigation

View full text Add to dashboard Cite

− Solid lipid nanoparticles (SLNs) have emerged to combine the advantages of polymeric nanoparticles and lipid emulsions in early 1990s. SLNs can present several desirable properties derived from the solid state core. When formulating SLNs, there should be careful considerations about the physical state of the inner solid lipid core and its polymorphism and supercooling behavior. In this review, SLNs were compared to lipid emulsion and emulsion of supercooled melt to understand the unusual behaviors compared to lipid emulsions and to have insights into stability and release mechanism. SLNs have been regarded as biocompatible system because lipids are usually well-tolerable ingredients than polymers. Several studies showed good tolerability of SLNs in terms of cytotoxicity and hemolysis. Similar to various other nanoparticulate drug delivery systems, SLNs can also change biodistribution of the incorporated drugs in a way to enhance therapeutic effect. Most of all, large scale production of SLNs was extablished wihtout using organic solvents. Although there is no SLN product in the market till date, several advantagious properties of SLNs and the progress we have seen so far would make commercial product of SLNs possible before long and encourage research community to apply SLN-based formulations for water-insoluble drugs.

show abstract

Section: Biodistributionmentioning

confidence: 99%

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

Li¹,

Lim²,

Choi³

et al. 2010

Journal of Pharmaceutical Investigation

View full text Add to dashboard Cite

show abstract

“…For SLNs loaded with different drugs, varied release profiles have been observed. Stealth and non-stealth tripalmitin SLNs loaded with paclitaxel have been prepared as an alternative parenteral administration, as the commercially available product Taxol is a toxicologically critical micellar solution of the drug in Cremaphor EL (Cavalli et al 1993). During sustained in-vitro release, 0.1% of the paclitaxel was released into the receptor medium (phosphate buffer, pH 7.4) after 120 min; this correlates to first pseudo zeroorder kinetics.…”

Section: Tissue Distribution and Drug Targeting Concentration Ofmentioning

confidence: 99%

Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles

Shenoy

Vijay

Murthy

2005

Journal of Pharmacy and Pharmacology

View full text Add to dashboard Cite

Cancer chemotherapeutic agents are often administered systemically. Following systemic administration, numerous biological factors associated with the tumours influence the delivery of the drugs to the tumours. These factors have been extensively studied for the last 2 decades. The influence of these biological factors has brought about a drastic change in the design of drug delivery systems to solid tumours. This review discusses the various biological factors influencing drug delivery to tumours and the subsequent development of injectable delivery systems (i.e., lipid-based nanoparticles (SLNs)) for adequate delivery of drug to solid tumours.

show abstract

“…by using different methods such as high pressure homogenization 9,10 , hot 11 and cold; ultrasonication, solvent evaporation, emulsification solvent diffusion, microemulsion 2 etc. Mechanisms for enhancing the oral bioavailability of drug molecules by SLNs include enhancing dissolution or solubilisation, stimulation of lymphatic transport, increasing gastric residence time, enhancing intestinal permeability, reducing metabolism and efflux activity, preventing first pass metabolism etc.…”

Section: Ms 13095mentioning

confidence: 99%

Formulation and Characterization of Solid Lipid Nanoparticles

Shanmukhi¹,

Nagabhushanam²,

Ashok³

et al. 2013

Journal of Pharmaceutical Research

View full text Add to dashboard Cite

In view of increasing bioavailability and percentage drug release by lymphatic drug delivery, Fosinopril loaded solid lipid nanoparticles were prepared by solvent emulsification and evaporation method. In vitro drug release studies revealed that 80% of the drug was being released from the optimized Fosinopril loaded solid lipid nanoparticles (SLNs) in 24hours. Optimized formulation and process parameters resulted in the production of Fosinopril loaded solid lipid nanoparticles with average particle size of 178.8 nm, zeta potential of -21mV and entrapment efficiency of 91.64% of 10 mg loading. In vitro characterization was carried out to evaluate the stability and release characteristics and kinetics. To analyze the release kinetics of drug from SLNs, drug release data was fitted into zero order, Korsmeyer-Peppas equation. Possible mechanisms for drug release might be anomalous diffusion or non-fickian diffusion. FTIR spectra, DSC thermograms revealed no significant interaction between drug and excipients. TEM photographs exhibited nanosized particles of Fosinopril. The stability studies performed for optimized SLN formulation at 4°C, 25°C, showed no significant change in % entrapment efficiency for one month. So, it was concluded that the optimized SLN formulation offers an efficient mode of delivery to the lipophilic antihypertensive drug, Fosinopril.

show abstract

Solid lipospheres of doxorubicin and idarubicin

Cited by 123 publications

References 4 publications

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

Solid Lipid Nanoparticles as Drug Delivery System for Water-Insoluble Drugs

Tumour targeting: biological factors and formulation advances in injectable lipid nanoparticles

Formulation and Characterization of Solid Lipid Nanoparticles

Contact Info

Product

Resources

About